ETNB(Delisted)
89bio·NASDAQ
--
--(--)
Signals Analysis
Bullish signal 1
Bearish signal 0
EPS Beats Expectation
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About ETNB
89bio, Inc.
A biopharmaceutical company focused on developing and commercializing innovative therapies for liver and metabolic disorders
655 Montgomery Street, Suite 1500, San Francisco, California 94111
--
89 Bio, Inc., was incorporated in June 2019 as a Delaware corporation to conduct the business of 89 Bio, Ltd., which was incorporated in Israel in January 2018. The Company is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases. The company's lead product candidate, pegozafermin, is a specially designed glycoglycolated analog of fibroblast growth factor that is currently being developed for the treatment of non-alcoholic steatohepatitis and for the treatment of severe hypertriglyceridemia.
Company Financials
EPS
ETNB has released its 2025 Q2 earnings. EPS was reported at -0.71, versus the expected -0.48, missing expectations. The chart below visualizes how ETNB has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
Related Symbols
No Data
You can ask Aime
No Data
